Epidermal growth factor

From Infogalactic: the planetary knowledge core
(Redirected from Epidermal growth factor-1)
Jump to: navigation, search

<templatestyles src="Module:Hatnote/styles.css"></templatestyles>

<templatestyles src="Module:Infobox/styles.css"></templatestyles>

Epidermal growth factor
1a3p egf.png
Rainbow colored NMR structure (N-terminus = blue, C-terminus = red) of the mouse epidermal growth factor.[1]
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols EGF ; HOMG4; URG
External IDs OMIM131530 MGI95290 HomoloGene1483 ChEMBL: 5734 GeneCards: EGF Gene
RNA expression pattern
PBB GE EGF 206254 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 1950 13645
Ensembl ENSG00000138798 ENSMUSG00000028017
UniProt P01133 P01132
RefSeq (mRNA) NM_001178130 NM_010113
RefSeq (protein) NP_001171601 NP_034243
Location (UCSC) Chr 4:
109.91 – 110.01 Mb
Chr 3:
129.68 – 129.76 Mb
PubMed search [1] [2]

Epidermal growth factor or EGF is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein[2] with 53 amino acid residues and three intramolecular disulfide bonds.[3]

Function

EGF results in cellular proliferation, differentiation, and survival.[4] EGF is a low-molecular-weight polypeptide first purified from the mouse submandibular gland, but since then found in many human tissues including submandibular gland, parotid gland. Salivary EGF, which seems also regulated by dietary inorganic iodine, also plays an important physiological role in the maintenance of oro-esophageal and gastric tissue integrity. The biological effects of salivary EGF include healing of oral and gastroesophageal ulcers, inhibition of gastric acid secretion, stimulation of DNA synthesis as well as mucosal protection from intraluminal injurious factors such as gastric acid, bile acids, pepsin, and trypsin and to physical, chemical and bacterial agents.[5]

Biological sources

Epidermal growth factor can be found in urine, saliva, milk, and plasma.[6] The production of epidermal growth factor has been found to be stimulated by testosterone.

Mechanism

File:MAPKpathway diagram.svg
Diagram showing key components of the MAPK/ERK pathway. In the diagram, "P" represents phosphate. Note EGF at the very top.

EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface. This stimulates ligand-induced dimerization,[7] activating the intrinsic protein-tyrosine kinase activity of the receptor (see the second diagram). The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cell - a rise in intracellular calcium levels, increased glycolysis and protein synthesis, and increases in the expression of certain genes including the gene for EGFR - that ultimately lead to DNA synthesis and cell proliferation.[8]

EGF-family

EGF is the founding member of the EGF-family of proteins. Members of this protein family have highly similar structural and functional characteristics. Besides EGF itself other family members include:[9]

All family members contain one or more repeats of the conserved amino acid sequence:

CX7CX4-5CX10-13CXCX8GXRC

Where X represents any amino acid.[9]

This sequence contains 6 cysteine residues that form three intramolecular disulfide bonds. Disulfide bond formation generates three structural loops that are essential for high-affinity binding between members of the EGF-family and their cell-surface receptors.[10]

EGF therapy

Increased activity of the epidermal growth factor receptor (EGFR) has been observed in certain types of cancer, often correlated with mutations in the receptor and abnormal function such as constitutive receptor signalling independent of the levels of EGF or of binding of EGF.[11] Thus EGF and/or EGFR have been exploited to develop imaging methods and targeted therapies against cancers overexpressing EGFR.

Pharmaceutical drugs developed for inhibiting the EGF receptor include gefitinib, erlotinib, afatinib and osimertinib for lung cancer, and Cetuximab for colon cancer. EGFR inhibitors are either tyrosine kinase inhibitors or monoclonal antibodies that slow down or halt cell growth. CimaVax-EGF, an active vaccine targeting EGF as the major ligand of EGF, raises antibodies against EGF itself, thereby denying EGFR-dependent cancers of a proliferative stimulus;[12] it is in use as a cancer therapy against non-small-cell lung carcinoma (the most common form of lung cancer) in Cuba, and is undergoing further trials for possible licensing in Japan, Europe, and the United States.[13]

Imaging agents have been developed which identify EGFR-dependent cancers using labeled EGF.[14] or anti-EGFR [15]

Interactions

Epidermal growth factor has been shown to interact with epidermal growth factor receptor.[16][17]

References

  1. PDB: 1a3p​; Lua error in package.lua at line 80: module 'strict' not found.
  2. Lua error in package.lua at line 80: module 'strict' not found.
  3. Lua error in package.lua at line 80: module 'strict' not found.
  4. Lua error in package.lua at line 80: module 'strict' not found.
  5. Lua error in package.lua at line 80: module 'strict' not found.
  6. Lua error in package.lua at line 80: module 'strict' not found.
  7. Lua error in package.lua at line 80: module 'strict' not found.
  8. Lua error in package.lua at line 80: module 'strict' not found.
  9. 9.0 9.1 Lua error in package.lua at line 80: module 'strict' not found.
  10. Lua error in package.lua at line 80: module 'strict' not found.
  11. Lurje G., et al., "EGFR Signalling and Drug Discovery", Oncology 77: 400-410 (2009)
  12. Lua error in package.lua at line 80: module 'strict' not found.
  13. Lua error in package.lua at line 80: module 'strict' not found.
  14. L. J. Lucas, C. A. Tellez , M. L. Castilho , C. L. D. Lee , M. A. Hupman , L. S. Vieira , I. Ferreira , L. Raniero , K. C. Hewitt. "Development of a sensitive, stable and EGFR-specific molecular imaging agent for surface enhanced Raman spectroscopy", Journal of Raman Spectroscopy DOI 10.1002/jrs.4678 (2015)
  15. L. J. Lucas , X. K. Chen , A. J. Smith , M. Korbelik , H. Zeng , P. W. K. Lee and K. C. Hewitt. "Aggregation of nanoparticles in endosomes and lysosomes produce Surface Enhanced Raman Spectroscopy", Journal of Nanophotonics 9: 093094-1-14 (2015).
  16. Lua error in package.lua at line 80: module 'strict' not found.
  17. Lua error in package.lua at line 80: module 'strict' not found.

Further reading

  • Lua error in package.lua at line 80: module 'strict' not found.
  • Lua error in package.lua at line 80: module 'strict' not found.
  • Lua error in package.lua at line 80: module 'strict' not found.

External links